Provided by Tiger Trade Technology Pte. Ltd.

Ocugen

1.87
-0.0900-4.59%
Post-market: 1.870.0001+0.01%19:53 EDT
Volume:6.24M
Turnover:11.80M
Market Cap:613.15M
PE:-8.29
High:1.96
Open:1.95
Low:1.86
Close:1.96
52wk High:2.73
52wk Low:0.5700
Shares:327.89M
Float Shares:306.73M
Volume Ratio:0.41
T/O Rate:2.03%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.2257
EPS(LYR):-0.2260
ROE:-776.89%
ROA:-63.10%
PB:-50.40
PE(LYR):-8.27

Loading ...

Ocugen Inc. Stock Falls Wednesday, Underperforms Market

Dow Jones
·
Jan 22

Ocugen Shares Drop After Stock Offering Prices

Dow Jones
·
Jan 22

BUZZ-U.S. STOCKS ON THE MOVE-Aligos, Intel, Travelers Companies

Reuters
·
Jan 21

Ocugen Prices $22.5 Million Stock Offering

MT Newswires Live
·
Jan 21

Ocugen prices 15M shares at $1.50 in underwritten offering

TIPRANKS
·
Jan 21

BRIEF-Ocugen Announces Pricing Of $22.5 Million Offering Of Common Stock

Reuters
·
Jan 21

Ocugen Inc - Announces Pricing of 15,000,000 Shares of Common Stock

THOMSON REUTERS
·
Jan 21

Ocugen Inc - Offering Price Set at $1.50 per Share for $22.5 Mln Proceeds

THOMSON REUTERS
·
Jan 21

Press Release: Ocugen, Inc. Announces Pricing of $22.5 Million Offering of Common Stock

Dow Jones
·
Jan 21

Ocugen Inc. Stock Falls Tuesday, Still Outperforms Market

Dow Jones
·
Jan 21

Ocugen Is Maintained at Buy by Chardan Capital

Dow Jones
·
Jan 20

Ocugen Inc. Stock Climbs 4.3%, Outperforms Market

Dow Jones
·
Jan 17

Ocugen Stock Is Surging Today: What's Driving The Action?

Benzinga_recent_news
·
Jan 17

Ocugen Inc. Stock Slides 13.8%, Underperforms Market

Dow Jones
·
Jan 16

Ocugen on Track for Largest Percent Decrease Since February 2024-- Data Talk

Dow Jones
·
Jan 16

Analysts’ Top Healthcare Picks: Regeneron (REGN), Ocugen (OCGN)

TIPRANKS
·
Jan 16

Ocugen's Early Gene Therapy Data Shows 46% Drop In Vision Damage

Benzinga_recent_news
·
Jan 16

Ocugen Reports Encouraging 12-Month Data for OCU410

TIPRANKS
·
Jan 15

BUZZ-Ocugen rises as gene therapy shows promise for blinding eye disease

Reuters
·
Jan 15

Ocugen Reports Positive Phase 2 Results for OCU410 Gene Therapy in Geographic Atrophy

Reuters
·
Jan 15